Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 2
Encontrada(s) 1 página(s)

Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Targeting the DSTYK-ULK1 axis rewires TNFR1 signaling to overcome treatment resistance in lung cancer

  • Pasquier, Andrea
  • Viu-Idocin, Cristina
  • Arricibita, Andrea
  • Echepare, Mirari
  • Picabea, Beñat
  • Orive, Daniel
  • Álava, Ane
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Argueta Allan
  • Molina, Eva
  • Pineda Lucena, Antonio
  • Gentili, Marco
  • Facchinetti, Federica
  • Roz, Luca
  • Montuenga, Luis M.
  • Valencia, Karmele
Immunotherapy has transformed the treatment of non-small cell lung cancer (NSCLC). Yet, acquired resistance remains a major clinical challenge. Defining molecular determinants of tumor sensitivity to T cell-mediated killing is therefore critical. Tumor necrosis factor α (TNF-α) released by cytotoxic T cells promotes tumor cell death, whereas NF-κB signaling supports survival. Autophagy counteracts TNFα-induced apoptosis, and its inhibition enhances responses to immune checkpoint inhibitors (ICIs). Genomic alterations further contribute to immune evasion and reduced immunotherapy efficacy. We previously identified DSTYK, a dual serine/threonine and tyrosine kinase amplified in NSCLC, as a suppressor of TNF-α-mediated CD8+ T cell killing and a driver of ICI resistance through autophagy. Here, we show that DSTYK modulates TNFR1 signaling by phosphorylating the autophagy initiator ULK1, which enables ULK1-dependent phosphorylation of RIPK1. Loss of DSTYK disrupts ULK1 activation, promotes RIPK1 autophosphorylation, proapoptotic signaling, and impaired NF-κB-dependent survival. These findings define a DSTYK-ULK1-RIPK1 axis controlling TNF-α-induced apoptosis and support targeting ULK1 to sensitize DSTYK-amplified NSCLC to T cell-mediated killing., FThis work was supported by FIMA, CIBERONC (CB16/12/00443), Fundación La Caixa, Spanish Ministry of Economy and Innovation, Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI22/00451 and PI23/00223), and the European Union Mission Cancer Program (SPACETIME and HORIZON-MISS-2023-CANCER-01). K.V. was supported by an investigator grant from the Asociación Española contra el cáncer (AECC) and a Ramón y Cajal contract; E.M. was supported by PFIS, Spanish Ministry of Health (ISCIII, Fondo de Investigación Sanitaria); C.V.-I. was supported by a Navarra Government predoctoral grant; D.O. was supported by FPU; and B.P. was supported by Zalain Jetetxea S.L., Conservas Martiko S.A., Ángel Cerdá S.L., and Nesucar S.L.
Academica-e. Repositorio Institucional de la Universidad Pública de Navarra
Publication Artículo científico (JournalArticle)

Establishment and characterization of an orthotopic implanted lung cancer model to mimic human tumor structure, microenvironment, and metastatic spread

  • Picabea, Beñat
  • Orive, Daniel
  • Rodríguez, Covadonga
  • Mailharin, Miren
  • Sangüesa Recalde, María
  • Houry, Maeva
  • Arricibita, Andrea
  • Echepare, Mirari
  • Álava, Ane
  • Viu-Idocin, Cristina
  • Calvo, Alfonso
  • Fernández Irigoyen, Joaquín
  • Santamaría Martínez, Enrique
  • Ariz Galilea, Mikel
  • Montuenga, Luis M.
  • Valencia, Karmele
Background: Subcutaneous (SC) lung tumor models are widely used in preclinical studies due to their technical simplicity but fail to recapitulate the complex microenvironment, immune landscape, and metastatic behavior of human lung cancers. These limitations hinder the translational value of such models, particularly in evaluating immunotherapies and metastasis-related mechanisms. There is a critical need for more physiologically relevant in vivo models that better reflect clinical tumor characteristics and disease progression. To address these limitations, we sought to develop a reproducible orthotopic lung cancer (LuO) model that enables detailed study of tumor progression, immune infiltration, and metastatic dynamics. Methods: we established and characterized a thoracotomy-based LuO model using a panel of human and murine lung cancer cell lines implanted into the pulmonary parenchyma of immunodeficient and syngeneic mice. Tumor progression was monitored longitudinally using bioluminescence imaging (BLI) and micro-computed tomography (CT). Comparative analyses with SC tumors were performed using immunohistochemistry, multiplexed immunofluorescence, transcriptomic and proteomic analyses. Circulating tumor cells (CTCs) and spontaneous metastases were isolated and functionally characterized. Results: the orthotopic model reliably generated solitary intrapulmonary tumors that closely mimic human lung cancer in growth pattern, vascularization, and progression. Compared to SC tumors, orthotopic tumors exhibited significantly enhanced vascular density, reduced hypoxia and DNA damage, and increased proliferation. Immune profiling revealed enriched and spatially organized infiltrates of CD4+ , CD8+ T cells, dendritic cells (DCs), and myeloid populations in orthotopic tumors, forming structures analogous to those found in patient tumors. Moreover, orthotopic tumors released CTCs capable of forming spontaneous and site-specific metastases to clinically relevant organs. Transcriptomic and proteomic profiling of metastasisderived cell lines uncovered conserved pro-metastatic signatures and niche-specific adaptations. Conclusions: this LuO model offers a reproducible, clinically relevant platform that captures important aspects of human lung cancer biology, including immune landscape, tumor microenvironment (TME), and metastatic progression. Its superior anatomical and immunological fidelity makes it a valuable preclinical tool for evaluating therapeutic strategies and dissecting molecular mechanisms of metastasis., This work was supported by Fundación para la Investigación Médica Aplicada (FIMA), Centro de Investigación Médica en Red de Cáncer (CIBERONC) (CB16/12/00443), Fundación La Caixa, Instituto de Salud Carlos III-Fondo de Investigación Sanitaria (FIS) program (PI22/00451 to L.M.M.), Spanish Ministry of Economy and Innovation and Fondo de Investigación Sanitaria-Fondo Europeo de Desarrollo Regional (PI23/00223 to K.V.), European Union Mission Cancer Program. SPACETIME, HORIZON-MISS-2023-CANCER-01 to L.M.M.